Quality of ADR reporting evaluated for remdesivir trials of COVID-19

被引:0
|
作者
机构
关键词
D O I
10.1007/s40278-020-84767-2
中图分类号
学科分类号
摘要
引用
收藏
页码:10 / 10
相关论文
共 50 条
  • [1] Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
    Kow, Chia Siang
    Aldeyab, Mamoon
    Hasan, Syed Shahzad
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 77 (03) : 435 - 437
  • [2] Quality of adverse event reporting in clinical trials of remdesivir in patients with COVID-19
    Chia Siang Kow
    Mamoon Aldeyab
    Syed Shahzad Hasan
    European Journal of Clinical Pharmacology, 2021, 77 : 435 - 437
  • [3] Critical reappraisal of remdesivir investigational trials in COVID-19
    Brouqui, P.
    Giraud-Gatineau, A.
    Raoult, D.
    NEW MICROBES AND NEW INFECTIONS, 2020, 38
  • [4] Remdesivir safety monitoring during the COVID-19 pandemic: A global review of adverse drug reaction (ADR) reporting in VigiBase
    Rocca, Elena
    Gauffin, Oskar
    Vidlin, Sara Hedfors
    Savage, Ruth
    Grundmark, Birgitta
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 324 - 324
  • [5] Remdesivir and COVID-19
    Francesco Ferrara
    Raffaele La Porta
    Vilma D’Aiuto
    Antonio Vitiello
    Irish Journal of Medical Science (1971 -), 2021, 190 : 1237 - 1238
  • [6] Remdesivir and COVID-19
    Wang, Lei-Yun
    Cui, Jia-Jia
    Ouyang, Qian-Ying
    Zhan, Yan
    Guo, Cheng-Xian
    Yin, Ji-Ye
    LANCET, 2020, 396 (10256): : 953 - 954
  • [7] Remdesivir in covid-19
    Ferner, Robin E.
    Aronson, Jeffrey K.
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 369
  • [8] Remdesivir and COVID-19
    Ferrara, Francesco
    La Porta, Raffaele
    D'Aiuto, Vilma
    Vitiello, Antonio
    IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (03) : 1237 - 1238
  • [9] Remdesivir for patients with COVID-19
    Wu, Peter E.
    Morris, Andrew M.
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2021, 193 (04) : E125 - E125